# Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers

Source: https://onco.cc/trials/nct04910386/  
OnCo record `nct04910386` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of envafolimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by 3D Medicines (Sichuan) Co., Ltd., not yet recruiting.

## Summary

Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers is a phase 2, randomised interventional study registered as NCT04910386 by 3D Medicines (Sichuan) Co., Ltd., with a registry enrolment figure of 126 participants, started 2027-06-01 and due to reach its primary completion in 2029-06. Interventions recorded: Envafolimab plus Gemcitabine&Cisplatin, Gemcitabine&Cisplatin. Conditions listed: Biliary Tract Neoplasms. Gallbladder cancer is named in the registry entry: "2. Subjects must have a histopathological or cytological diagnosis of locally advanced or metastatic gallbladder cancer (GBC) or cholangiocarcinoma (CCA);". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT04910386
- Phase: 2
- Setting: A Randomized, Open-Label, Multicenter Phase 2 Study of Envafolimab in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients With Locally Advanced or Metastatic Biliary Tract Cancers
- Sponsor: 3D Medicines (Sichuan) Co., Ltd.
- Enrolled: 126

## Sources

- ClinicalTrials.gov NCT04910386: https://clinicaltrials.gov/study/NCT04910386

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Envafolimab](https://onco.cc/drugs/envafolimab/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct04910386.json